Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 5693

1.

Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment [Internet].

Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jan.

2.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.

N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.

3.

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.

Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators.

Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28.

4.

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.

van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T.

Kidney Int. 2011 Jun;79(12):1341-52. doi: 10.1038/ki.2010.536. Epub 2011 Feb 9.

5.

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J; Chronic Kidney Disease Prognosis Consortium, Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, de Zeeuw D, Rossing P, Parving HH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T.

Kidney Int. 2011 Jun;79(12):1331-40. doi: 10.1038/ki.2010.550. Epub 2011 Feb 2.

6.

Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J; Chronic Kidney Disease Prognosis Consortium.

Kidney Int. 2011 Jul;80(1):93-104. doi: 10.1038/ki.2010.531. Epub 2011 Feb 2.

7.

Executive summary: standards of medical care in diabetes--2011.

American Diabetes Association.

Diabetes Care. 2011 Jan;34 Suppl 1:S4-10. doi: 10.2337/dc11-S004. Review. No abstract available.

8.

Standards of medical care in diabetes--2011.

American Diabetes Association.

Diabetes Care. 2011 Jan;34 Suppl 1:S11-61. doi: 10.2337/dc11-S011. No abstract available.

10.

The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.

Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU.

Kidney Int. 2011 Jul;80(1):17-28. doi: 10.1038/ki.2010.483. Epub 2010 Dec 8. Erratum in: Kidney Int. 2011 Nov;80(9):1000.

11.

Evaluation and management of special subgroups after primary percutaneous coronary intervention.

De Luca L, Tomai F, Verdoia M, De Luca G.

Am Heart J. 2010 Dec;160(6 Suppl):S22-7. doi: 10.1016/j.ahj.2010.10.012.

PMID:
21147288
12.

Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion.

Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, Sugiyama Y.

Clin Pharmacol Ther. 2011 Jan;89(1):81-8. doi: 10.1038/clpt.2010.232. Epub 2010 Dec 1.

PMID:
21124314
13.

Pharmacological treatments for fatigue associated with palliative care.

Peuckmann V, Elsner F, Krumm N, Trottenberg P, Radbruch L.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006788. doi: 10.1002/14651858.CD006788.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD006788.

PMID:
21069692
14.

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R.

Lancet. 2010 Nov 13;376(9753):1658-69. doi: 10.1016/S0140-6736(10)60310-8. Epub 2010 Nov 8. Erratum in: Lancet. 2011 Jan 8;377(9760):126.

15.

Protective role of vitamin C and E against sodium arsenate induced changes in developing kidney of albino mice.

Qureshi F, Tahir M, Sami W.

J Ayub Med Coll Abbottabad. 2009 Oct-Dec;21(4):63-9.

PMID:
21067028
16.

Anemia therapy in kidney disease. What research reveals about ESA medication safety.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2010 Nov;22(9):1-2, 7. No abstract available.

PMID:
21066834
17.

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, Hauser T, Neumann I, Tesar V, Wissing KM, Pagnoux C, Schmitt W, Jayne DR; European Vasculitis Study Group (EUVAS).

JAMA. 2010 Dec 1;304(21):2381-8. doi: 10.1001/jama.2010.1658. Epub 2010 Nov 8.

PMID:
21060104
18.

Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials).

Garg P, Charytan DM, Novack L, Cutlip DE, Popma JJ, Moses J, Leon MB, Schofer J, Breithardt G, Schampaert E, Mauri L.

Am J Cardiol. 2010 Nov 15;106(10):1436-42. doi: 10.1016/j.amjcard.2010.07.011.

PMID:
21059433
19.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D.

Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.

PMID:
21055801
20.

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Andersen S, Mischak H, Zürbig P, Parving HH, Rossing P.

BMC Nephrol. 2010 Nov 1;11:29. doi: 10.1186/1471-2369-11-29.

Supplemental Content

Support Center